stockrowImmunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) EPS (diluted)
Immunome, Inc.'s EPS (diluted) for fiscal 2025 was −$2.43, compared with −$5.00 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.53. Over the past ten years it has ranged from −$9.55 (fiscal 2019) to −$2.14 (fiscal 2021); the current reading is higher than 88% of that period. Immunome, Inc. ranks 355th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$2.43 | — |
| FY2024 | −$5.00 | — |
| FY2023 | −$5.38 | — |
| FY2022 | −$3.09 | — |
| FY2021 | −$2.14 | — |
| FY2020 | −$5.26 | — |
| FY2019 | −$9.55 | — |
| FY2018 | −$7.22 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.65 | — |
| Mar 2026 | −$0.48 | — |
| Dec 2025 | −$0.75 | — |
| Sep 2025 | −$0.65 | — |
| 23 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $2.29 |
| ADMA ADMA Biologics Inc compare | $0.77 |
| VCEL Vericel Corporation compare | $0.65 |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$0.29 |
| IMNM Immunome, Inc. | −$2.53 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
| PVLA Palvella Therapeutics, Inc. compare | −$4.83 |
| VERA Vera Therapeutics, Inc. compare | −$5.86 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on IMNM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement